The United States Food and Drug Administration has granted approval for the initial oral form of a GLP-1 medication intended for weight reduction, a step that could substantially broaden the reach of obesity therapies.
Produced by the Danish pharmaceutical company Novo Nordisk, the once-daily Wegovy tablet is slated to become available in early January. Novo Nordisk reports that individuals participating in clinical studies who used the Wegovy pill experienced an average loss of 16.6% in their total body weight.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Health tracking applications such as Shotlee can assist users in monitoring their progress during weight loss journeys when combined with these treatments.